EGFR UNCOMMON MUTATIONS
Clinical trials for EGFR UNCOMMON MUTATIONS explained in plain language.
Never miss a new study
Get alerted when new EGFR UNCOMMON MUTATIONS trials appear
Sign up with your email to follow new studies for EGFR UNCOMMON MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Matched conditions: EGFR UNCOMMON MUTATIONS
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo therapy targets rare lung cancer mutation
Disease control Recruiting nowThis study tests a new drug (firmonertinib) combined with radiation therapy for people with a specific type of stage III lung cancer that cannot be removed by surgery. The cancer must have a rare change in the EGFR gene. The goal is to see if the combination can delay cancer grow…
Matched conditions: EGFR UNCOMMON MUTATIONS
Phase: PHASE2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC